Yale study identifies molecular mechanism behind some lissencephaly disorders

Lissencephaly is a spectrum of rare, genetic disorders in which the brain fails to develop its hallmark folds.

Ketamine’s long-lasting antidepressant effects unveiled in new study

Persistent blocking of NMDAR and burst-type firing by lateral habenula (LHb) neurons may offer a basis for the long-lasting antidepressant effects of ketamine.

October 23, 2023

Gilead to snap up liver disease biotech CymaBay for $4.3B

Gilead is betting $4.3 billion on a biotech six months before the FDA is expected to make an approval decision on its rare liver disease

February 13, 2024

Ro’s weight loss business more than doubled in the last year. Now it’s trying to prove its program works

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.